These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22952334)

  • 21. "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
    Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
    Leukemia; 2022 May; 36(5):1436-1439. PubMed ID: 35277655
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 23. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
    Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
    Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
    [No Abstract]   [Full Text] [Related]  

  • 25. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
    Göhring G; Giagounidis A; Büsche G; Hofmann W; Kreipe HH; Fenaux P; Hellström-Lindberg E; Schlegelberger B
    Haematologica; 2011 Feb; 96(2):319-22. PubMed ID: 21109690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
    Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
    N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 34. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
    Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
    Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 37. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
    Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
    List AF
    Cancer Control; 2006 Dec; 13 Suppl():12-6. PubMed ID: 17242662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.